Fda Approves The First Interchangeable Biosimilar For Humira
The Food and Drug Administration recently approved Cyltezo (adalimumab-adbm), the first interchangeable biosimilar product of Humira (adalimumab). Key Takeaways The Food and Drug Administration has approved Cyltezo, an interchangeable biosimilar of Humira (adalimumab)There are other biosimilars of Humira, but Cyltezo is the first that is also interchangeable, which means that pharmacists can substitute it for Humira in some states.Cyltezo is expected to cost less than Humira, but the price has not been set as yet, and it will not be marketed until July 2023 due to patent protection on Humira....